Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Relative Ratios of Human Seasonal Coronavirus Antibodies Predict the Efficiency of Cross-Neutralization of SARS-CoV-2 Spike Binding to ACE2

Yannick Galipeau, Vinayakumar Siragam, Geneviève Laroche, Erika Marion, Matthew Greig, Michaeline McGuinty, Ronald A Booth, Yves Durocher, Miroslava Cuperlovic-Culf, Steffany A.L. Bennett, Angela M. Crawley, Patrick M. Giguère, Curtis Cooper, View ORCID ProfileMarc-André Langlois
doi: https://doi.org/10.1101/2021.07.16.21260079
Yannick Galipeau
1Department of Biochemistry, Microbiology & Immunology, Faculty of Medicine, University of Ottawa, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vinayakumar Siragam
1Department of Biochemistry, Microbiology & Immunology, Faculty of Medicine, University of Ottawa, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Geneviève Laroche
1Department of Biochemistry, Microbiology & Immunology, Faculty of Medicine, University of Ottawa, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erika Marion
1Department of Biochemistry, Microbiology & Immunology, Faculty of Medicine, University of Ottawa, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew Greig
1Department of Biochemistry, Microbiology & Immunology, Faculty of Medicine, University of Ottawa, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michaeline McGuinty
2The Ottawa Hospital Research Institute
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronald A Booth
3University of Ottawa & The Ottawa Hospital Department of Pathology and Laboratory Medicine and The Eastern Ontario Regional Laboratory Association (EORLA).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yves Durocher
4Human Health Therapeutics Research Center, National Research Council Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miroslava Cuperlovic-Culf
1Department of Biochemistry, Microbiology & Immunology, Faculty of Medicine, University of Ottawa, Canada.
5Digital Technologies Research Center, National Research Council Canada
6Ottawa Institute of Systems Biology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steffany A.L. Bennett
1Department of Biochemistry, Microbiology & Immunology, Faculty of Medicine, University of Ottawa, Canada.
6Ottawa Institute of Systems Biology
7University of Ottawa Centre for Infection, Immunity and Inflammation (CI3)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angela M. Crawley
1Department of Biochemistry, Microbiology & Immunology, Faculty of Medicine, University of Ottawa, Canada.
2The Ottawa Hospital Research Institute
7University of Ottawa Centre for Infection, Immunity and Inflammation (CI3)
8Department of Biology, Carleton University, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick M. Giguère
1Department of Biochemistry, Microbiology & Immunology, Faculty of Medicine, University of Ottawa, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Curtis Cooper
2The Ottawa Hospital Research Institute
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc-André Langlois
1Department of Biochemistry, Microbiology & Immunology, Faculty of Medicine, University of Ottawa, Canada.
7University of Ottawa Centre for Infection, Immunity and Inflammation (CI3)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marc-André Langlois
  • For correspondence: langlois{at}uottawa.ca
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Antibodies raised against highly prevalent human seasonal coronaviruses (sCoVs), which are responsible for the common cold, are known to cross-react with SARS-CoV-2 antigens. This cross-reactivity prompts questions about their protective role against SARS-CoV-2 infections and COVID-19 disease severity. However, the relationship between sCoV exposure and SARS-CoV-2 correlates of protection have not been clearly identified. Here we performed a cross-sectional analysis of cross-reactivity and cross-neutralization to three SARS-CoV-2 antigens using pre-pandemic serum from four different groups: pediatrics and adolescents (<21 yrs of age), persons 21 to 70 yrs of age, persons older than 70 yrs of age, and persons living with HCV or HIV. We find that antibody cross-reactivity to SARS-CoV-2 antigens varied between 1.6% and 15.3% depending on the cohort and the isotype-antigen pair analyzed. We also demonstrate a broad range of neutralizing activity (0-45%) in pre-pandemic serum that interferes with SARS-CoV-2 spike attachment to ACE2. While the abundance of sCoV antibodies did not directly correlate with neutralization efficiency, by using machine learning methodologies, we show that neutralizing activity is rather dependent on the latent variables related to the pattern ratios of sCoVs antibodies presented by each person. These were independent of age or sex, and could be accurately predicted by comparing the relative ratios of IgGs in sera directed to NL63, 229E, HKU-1, and OC43 spike proteins. More specifically, we identified antibodies to NL63 and OC43 as being the two most important predictors of latent variables responsible for protection, and 229E as being the least weighted. Our data support that exposure to sCoVs triggers various cellular and immune responses that influence the efficiency of SARS-CoV-2 spike binding to ACE2, and may impact COVID-19 disease severity through various other latent variables.

Figure
  • Download figure
  • Open in new tab

Graphical abstract

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

none

Funding Statement

This study was supported in part by a COVID-19 Rapid Response grant by the Canadian Institute of Health Research (CIHR) and by a grant supplement by the Canadian Immunity Task Force (CITF) to M-A Langlois and by the National Research Council of Canada Collaborative R&D Initiative Pandemic Response Challenge Program Grant to SAL Bennett and M Cuperlovic-Culf (PR031-1).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Use of human samples for this study was approved by the University of Ottawa Ethics Review Board: Certificates H-04-20-5727, H-04-21-6643 and H-07-20-6009.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Author middle initial added Patrick M. Giguere

Data Availability

All the study raw data will be made publicly available upon request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted July 18, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Relative Ratios of Human Seasonal Coronavirus Antibodies Predict the Efficiency of Cross-Neutralization of SARS-CoV-2 Spike Binding to ACE2
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Relative Ratios of Human Seasonal Coronavirus Antibodies Predict the Efficiency of Cross-Neutralization of SARS-CoV-2 Spike Binding to ACE2
Yannick Galipeau, Vinayakumar Siragam, Geneviève Laroche, Erika Marion, Matthew Greig, Michaeline McGuinty, Ronald A Booth, Yves Durocher, Miroslava Cuperlovic-Culf, Steffany A.L. Bennett, Angela M. Crawley, Patrick M. Giguère, Curtis Cooper, Marc-André Langlois
medRxiv 2021.07.16.21260079; doi: https://doi.org/10.1101/2021.07.16.21260079
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Relative Ratios of Human Seasonal Coronavirus Antibodies Predict the Efficiency of Cross-Neutralization of SARS-CoV-2 Spike Binding to ACE2
Yannick Galipeau, Vinayakumar Siragam, Geneviève Laroche, Erika Marion, Matthew Greig, Michaeline McGuinty, Ronald A Booth, Yves Durocher, Miroslava Cuperlovic-Culf, Steffany A.L. Bennett, Angela M. Crawley, Patrick M. Giguère, Curtis Cooper, Marc-André Langlois
medRxiv 2021.07.16.21260079; doi: https://doi.org/10.1101/2021.07.16.21260079

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (427)
  • Allergy and Immunology (753)
  • Anesthesia (220)
  • Cardiovascular Medicine (3284)
  • Dentistry and Oral Medicine (362)
  • Dermatology (275)
  • Emergency Medicine (478)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1166)
  • Epidemiology (13346)
  • Forensic Medicine (19)
  • Gastroenterology (898)
  • Genetic and Genomic Medicine (5138)
  • Geriatric Medicine (480)
  • Health Economics (781)
  • Health Informatics (3260)
  • Health Policy (1140)
  • Health Systems and Quality Improvement (1189)
  • Hematology (428)
  • HIV/AIDS (1015)
  • Infectious Diseases (except HIV/AIDS) (14616)
  • Intensive Care and Critical Care Medicine (912)
  • Medical Education (476)
  • Medical Ethics (126)
  • Nephrology (522)
  • Neurology (4908)
  • Nursing (262)
  • Nutrition (725)
  • Obstetrics and Gynecology (880)
  • Occupational and Environmental Health (795)
  • Oncology (2517)
  • Ophthalmology (722)
  • Orthopedics (280)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (541)
  • Pediatrics (1299)
  • Pharmacology and Therapeutics (548)
  • Primary Care Research (555)
  • Psychiatry and Clinical Psychology (4197)
  • Public and Global Health (7489)
  • Radiology and Imaging (1703)
  • Rehabilitation Medicine and Physical Therapy (1010)
  • Respiratory Medicine (979)
  • Rheumatology (479)
  • Sexual and Reproductive Health (495)
  • Sports Medicine (424)
  • Surgery (547)
  • Toxicology (72)
  • Transplantation (235)
  • Urology (203)